List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2287177/publications.pdf Version: 2024-02-01



NINC REN

#	Article	IF	CITATIONS
1	MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology, 2013, 58, 158-170.	3.6	260
2	Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. Journal of Hepatology, 2007, 47, 684-690.	1.8	176
3	Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology, 2008, 48, 1834-1842.	3.6	149
4	Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma. Clinical Cancer Research, 2013, 19, 3944-3954.	3.2	108
5	Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. International Journal of Biological Sciences, 2020, 16, 1551-1562.	2.6	99
6	Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97â€H cell line. Cancer Science, 2010, 101, 2546-2553.	1.7	90
7	Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. Redox Biology, 2021, 41, 101942.	3.9	88
8	Diagnosis and treatment of hepatic angiomyolipoma in 26 cases. World Journal of Gastroenterology, 2003, 9, 1856.	1.4	87
9	Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. Journal of Surgical Oncology, 2007, 96, 37-45.	0.8	85
10	Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1073-1080.	1.2	81
11	The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2006, 132, 709-717.	1.2	77
12	CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. Journal of Hematology and Oncology, 2020, 13, 11.	6.9	73
13	Identification of Suitable Reference Genes for qRT-PCR Analysis of Circulating microRNAs in Hepatitis B Virus-Infected Patients. Molecular Biotechnology, 2012, 50, 49-56.	1.3	71
14	The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2006, 132, 399-407.	1.2	70
15	SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Theranostics, 2020, 10, 4627-4643.	4.6	61
16	Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget, 2016, 7, 12997-13012.	0.8	58
17	Suitable reference genes for real-time PCR in human HBV-related hepatocellular carcinoma with different clinical prognoses. BMC Cancer, 2009, 9, 49.	1.1	56
18	Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. Hepatology, 2013, 57, 1024-1034.	3.6	56

#	Article	IF	CITATIONS
19	The various aspects of genetic and epigenetic toxicology: testing methods and clinical applications. Journal of Translational Medicine, 2017, 15, 110.	1.8	52
20	Identification of MSRA gene on chromosome 8p as a candidate metastasis suppressor for human hepatitis B virus-positive hepatocellular carcinoma. BMC Cancer, 2007, 7, 172.	1.1	50
21	Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection. Gut, 2010, 59, 1699-1708.	6.1	48
22	MicroRNA-29a-5p Is a Novel Predictor for Early Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection. PLoS ONE, 2012, 7, e52393.	1.1	48
23	Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World Journal of Gastroenterology, 2006, 12, 3911.	1.4	47
24	Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology, 2010, 52, 2012-2022.	3.6	45
25	The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1-7.	1.2	37
26	Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2017, 21, 1471-1479.	0.9	35
27	Integrated Analysis of Copy Number Variations and Gene Expression Profiling in Hepatocellular carcinoma. Scientific Reports, 2017, 7, 10570.	1.6	33
28	Silencing GTSE-1 expression inhibits proliferation and invasion of hepatocellular carcinoma cells. Cell Biology and Toxicology, 2016, 32, 263-274.	2.4	32
29	Long non-coding RNA00364 represses hepatocellular carcinoma cell proliferation via modulating p-STAT3-IFIT2 signaling axis. Oncotarget, 2017, 8, 102006-102019.	0.8	30
30	Long Non-coding RNAs are Differentially Expressed in Hepatocellular Carcinoma Cell Lines with Differing Metastatic Potential. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10513-10524.	0.5	30
31	A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2019, 9, 1160.	1.3	29
32	Loss of Heterozygosity at D8S298 Is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma. Clinical Cancer Research, 2007, 13, 7363-7369.	3.2	28
33	Mesenchymal stem cells seldomly fuse with hepatocellular carcinoma cells and are mainly distributed in the tumor stroma in mouse models. Oncology Reports, 2013, 29, 713-719.	1.2	28
34	High GCLC level in tumor tissues is associated with poor prognosis of hepatocellular carcinoma after curative resection. Journal of Cancer, 2019, 10, 3333-3343.	1.2	28
35	Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression. American Journal of Cancer Research, 2016, 6, 1873-1889.	1.4	28
36	Combination of Osteopontin with Peritumoral Infiltrating Macrophages is Associated with Poor Prognosis of Early-Stage Hepatocellular Carcinoma after Curative Resection. Annals of Surgical Oncology, 2014, 21, 1304-1313.	0.7	27

#	Article	IF	CITATIONS
37	Osteopontin promotes hepatocellular carcinoma progression via the PI3K/AKT/Twist signaling pathway. Oncology Letters, 2018, 16, 5299-5308.	0.8	26
38	Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. Cancer Letters, 2010, 290, 204-210.	3.2	25
39	Association of Specific Genotypes in Metastatic Suppressor HTPAP with Tumor Metastasis and Clinical Prognosis in Hepatocellular Carcinoma. Cancer Research, 2011, 71, 3278-3286.	0.4	25
40	PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy. Journal of Hepatology, 2022, 77, 140-151.	1.8	20
41	Abdominal Drainage Was Unnecessary After Hepatectomy Using the Conventional Clamp Crushing Technique. Journal of Gastrointestinal Surgery, 2006, 10, 302-308.	0.9	19
42	Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk. Tumor Biology, 2014, 35, 4007-4015.	0.8	19
43	Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. Journal of Cancer Research and Clinical Oncology, 2010, 136, 595-601.	1.2	18
44	TGF beta1 and related-Smads contribute to pulmonary metastasis of hepatocellular carcinoma in mice model. Journal of Experimental and Clinical Cancer Research, 2012, 31, 93.	3.5	17
45	Low expression of <scp>WW</scp> domainâ€containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Cancer Medicine, 2018, 7, 3031-3043.	1.3	16
46	High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection. Annals of Translational Medicine, 2020, 8, 466-466.	0.7	16
47	Whole-Exome Sequencing-Based Mutational Profiling of Hepatitis B Virus-Related Early-Stage Hepatocellular Carcinoma. Gastroenterology Research and Practice, 2017, 2017, 1-7.	0.7	14
48	A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma. International Journal of Biological Sciences, 2019, 15, 2282-2295.	2.6	14
49	Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 907-918.	1.8	14
50	Organ microenvironment affects growth and metastasis of hepatocellular carcinoma via the TGF-β/Smad pathway in mice. Experimental and Therapeutic Medicine, 2013, 5, 133-137.	0.8	12
51	Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma. Clinical and Experimental Medicine, 2020, 20, 329-337.	1.9	12
52	Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. Annals of Translational Medicine, 2020, 8, 1301-1301.	0.7	11
53	The spatial distribution of immune cell subpopulations in hepatocellular carcinoma. Cancer Science, 2022, 113, 423-431.	1.7	11
54	Genome-Wide Association Study Identifies a Genetic Prediction Model for Postoperative Survival in Patients with Hepatocellular Carcinoma. Medical Science Monitor, 2019, 25, 2452-2478.	0.5	10

#	Article	IF	CITATIONS
55	Development and validation of a nomogram combining hematological and imaging features for preoperative prediction of microvascular invasion in hepatocellular carcinoma patients. Annals of Translational Medicine, 2021, 9, 402-402.	0.7	8
56	Integrated analysis of the impact of age on genetic and clinical aspects of hepatocellular carcinoma. Aging, 2018, 10, 2079-2097.	1.4	6
57	Association of WWOX rs9926344 polymorphism with poor prognosis of hepatocellular carcinoma. Journal of Cancer, 2018, 9, 1239-1247.	1.2	6
58	The association between KLF4 as a tumor suppressor and the prognosis of hepatocellular carcinoma after curative resection. Aging, 2020, 12, 15566-15580.	1.4	6
59	High RPS3A expression correlates with low tumor immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patients. American Journal of Cancer Research, 2020, 10, 2768-2784.	1.4	6
60	Downregulation of HTPAP transcript variant 1 correlates with tumor metastasis and poor survival in patients with hepatocellular carcinoma. Cancer Science, 2011, 102, 583-590.	1.7	5
61	Progress in quantitative technique of circulating cell free DNA and its role in cancer diagnosis and prognosis. Cancer Genetics, 2019, 239, 75-84.	0.2	5
62	Laparoscopic versus open left hemihepatectomy for hepatocellular carcinoma: a propensity score matching analysis. Translational Cancer Research, 2020, 9, 5484-5492.	0.4	3
63	Development and Validation of a Metabolic Gene-Based Prognostic Signature for Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 193-209.	1.8	3
64	Effect of postoperative apatinib treatment after resection of hepatocellular carcinoma with portal vein invasion: A phase II study Journal of Clinical Oncology, 2020, 38, 514-514.	0.8	3
65	The Age-Specific Features and Clinical Significance of NRF2 and MAPK10 Expression in HCC Patients. International Journal of General Medicine, 2022, Volume 15, 737-748.	0.8	2
66	Identification of a novel Calpain-2-SRC feed-back loop as necessity for β-Catenin accumulation and signaling activation in hepatocellular carcinoma. Oncogene, 2022, 41, 3554-3569.	2.6	2
67	Genomic Aberrations in the HTPAP Promoter Affect Tumor Metastasis and Clinical Prognosis of Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e90528.	1.1	1
68	The predictive value of chromosome 8p deletion for metastasis of hepatocellular carcinoma: a summary of works in 10 years. Frontiers of Medicine in China, 2008, 2, 211-215.	0.1	0
69	A Novel mRNA Signature Related to Immunity to Predict Survival and Immunotherapy Response in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2022 <u>, 000, 000-000</u> .	0.7	0